7/1/2013 8:04:36 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SARATOGA, Calif.--(BUSINESS WIRE)--The Myelin Repair Foundation (MRF) today has granted a non-exclusive sublicense to Biogen Idec (NASDAQ: BIIB) for the use of MRF’s technologies to generate a novel mouse model for all demyelinating diseases, including multiple sclerosis (MS). Biogen Idec, an independent biotechnology company with a strong focus on multiple sclerosis therapies, will use the MRF technology in its in-house drug discovery programs. The Myelin Repair Foundation and Biogen Idec will collaborate to improve the licensed technologies to enhance discovery of myelin repair therapeutics and speed clinical development.
Help employers find you! Check out all the jobs and post your resume.
comments powered by